According to 2022 guidelines (SEAP/SEOM) for NSCLC, it is recommended to assess the mutational status of EGFR, BRAF, KRAS, and MET, as well as ALK, ROS1, NTRK, and RET translocations and PD-L1 expression levels. Here, CD274 is linked to non-small cell lung carcinoma.